Unlike behavioral interventions that rely primarily on conscious willpower and dietary restriction, GLP-1 medications address weight management at a fundamental biological level
General inflammatory markers: High-sensitivity CRP (hs-CRP), the most responsive general marker Erythrocyte sedimentation rate (ESR) Fibrinogen Condition-specific markers: Rheumatoid arthritis: RF, anti-CCP, DAS28 score Hashimoto thyroiditis: TPO antibodies, thyroglobulin antibodies, TSH Psoriasis: PASI score, BSA involvement IBD: Fecal calprotectin, SES-CD or Mayo score Lupus: ANA, anti-dsDNA, complement C3/C4 Cytokine panels (when available): TNF-alpha IL-6 IL-1 beta IL-17 (particularly relevant for psoriasis and spondyloarthritis) The recommendation from most practitioners is baseline testing before starting, a 4 to 6 week interim check, and a full reassessment at 12 weeks
Signals from the niche: Insights into the role of IGF-1 and IL-6 in modulating skeletal muscle fibrosis
Tirzepatide: The Dual Agonist Tirzepatide is often referred to as the next generation GLP-1 because it targets two hormones : This dual mechanism seems to amplify its effects
Solubility: Reconstitute with bacteriostatic water for best results